Open | - |
Close | - |
Volume / Avg. | 0 / 368.889K |
Day Range | - - - |
52 Wk Range | 8.210 - 12.030 |
Market Cap | $416.625M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 43 |
Short Interest | % |
Days to Cover | 31.74 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Theravance Biopharma (NASDAQ: TBPH) through any online brokerage.
Other companies in Theravance Biopharma’s space includes: Atea Pharmaceuticals (NASDAQ:AVIR), Third Harmonic Bio (NASDAQ:THRD), Zevra Therapeutics (NASDAQ:ZVRA), GH Research (NASDAQ:GHRS) and SNDL (NASDAQ:SNDL).
The latest price target for Theravance Biopharma (NASDAQ: TBPH) was reported by HC Wainwright & Co. on Tuesday, August 8, 2023. The analyst firm set a price target for 20.00 expecting TBPH to rise to within 12 months (a possible 131.21% upside). 2 analyst firms have reported ratings in the last year.
The stock price for Theravance Biopharma (NASDAQ: TBPH) is $8.65 last updated March 18, 2024 at 4:16 PM EDT.
There are no upcoming dividends for Theravance Biopharma.
Theravance Biopharma’s Q1 earnings are confirmed for Monday, May 6, 2024.
There is no upcoming split for Theravance Biopharma.
Theravance Biopharma is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.